Edmp, Inc. Abb Vie Inc. Transaction History

Edmp, Inc.

$120 Million
Q3 2024

A detailed history of Edmp, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Edmp, Inc. holds 26,274 shares of ABBV stock, worth $4.61 Million. This represents 4.31% of its overall portfolio holdings.

Number of Shares

26,274

Previous 28,662 8.33%

Holding current value

$4.61 Million

Previous $4.92 Million 5.53%

% of portfolio

4.31%

Previous 4.51%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$163.84 - $199.33 $391,249 - $476,000	-2,388 Reduced 8.33%	26,274 $5.19 Million
Q2 2024 Jul 31, 2024	SELL	$154.79 - $180.76 $34,982 - $40,851	-226 Reduced 0.78%	28,662 $4.92 Million
Q1 2024 Apr 24, 2024	BUY	$159.82 - $182.1 $8,470 - $9,651	53 Added 0.18%	28,888 $5.26 Million
Q4 2023 Jan 25, 2024	SELL	$137.6 - $154.97 $35,363 - $39,827	-257 Reduced 0.88%	28,835 $4.47 Million
Q3 2023 Oct 23, 2023	SELL	$133.59 - $154.65 $319,280 - $369,613	-2,390 Reduced 7.59%	29,092 $4.34 Million
Q2 2023 Jul 24, 2023	SELL	$132.51 - $164.9 $20,274 - $25,229	-153 Reduced 0.48%	31,482 $4.24 Million
Q1 2023 Apr 20, 2023	SELL	$144.61 - $166.54 $122,629 - $141,225	-848 Reduced 2.61%	31,635 $5.04 Million
Q4 2022 Feb 06, 2023	SELL	$138.31 - $165.87 $722 Million - $865 Million	-5,217,095 Reduced 99.38%	32,483 $5.25 Million
Q4 2022 Feb 01, 2023	BUY	$138.31 - $165.87 $721 Million - $865 Million	5,216,157 Added 15607.42%	5,249,578 $849 Million
Q3 2022 Oct 20, 2022	SELL	$134.21 - $153.93 $33,820 - $38,790	-252 Reduced 0.75%	33,421 $4.49 Million
Q2 2022 Jul 28, 2022	SELL	$137.62 - $174.96 $38,533 - $48,988	-280 Reduced 0.82%	33,673 $5.16 Million
Q1 2022 Apr 28, 2022	BUY	$131.98 - $163.75 $159,431 - $197,810	1,208 Added 3.69%	33,953 $5.5 Million
Q4 2021 Jan 19, 2022	SELL	$107.43 - $135.93 $64,350 - $81,422	-599 Reduced 1.8%	32,745 $4.43 Million
Q3 2021 Oct 20, 2021	BUY	$106.4 - $120.78 $169,495 - $192,402	1,593 Added 5.02%	33,344 $3.6 Million
Q2 2021 Jul 19, 2021	BUY	$105.21 - $117.21 $18,937 - $21,097	180 Added 0.57%	31,751 $3.58 Million
Q1 2021 Apr 20, 2021	SELL	$102.3 - $112.62 $64,039 - $70,500	-626 Reduced 1.94%	31,571 $3.42 Million
Q4 2020 Jan 12, 2021	SELL	$80.49 - $108.67 $50,708 - $68,462	-630 Reduced 1.92%	32,197 $3.45 Million
Q3 2020 Oct 20, 2020	SELL	$85.91 - $100.83 $70,875 - $83,184	-825 Reduced 2.45%	32,827 $2.88 Million
Q2 2020 Jul 20, 2020	SELL	$73.37 - $98.18 $446,529 - $597,523	-6,086 Reduced 15.32%	33,652 $3.3 Million
Q1 2020 Apr 20, 2020	SELL	$64.5 - $97.79 $105,328 - $159,691	-1,633 Reduced 3.95%	39,738 $3.03 Million
Q4 2019 Jan 21, 2020	BUY	$72.13 - $90.25 $117,932 - $147,558	1,635 Added 4.11%	41,371 $3.66 Million
Q3 2019 Oct 16, 2019	BUY	$62.98 - $75.72 $166,330 - $199,976	2,641 Added 7.12%	39,736 $2.96 Million
Q2 2019 Jul 25, 2019	SELL	$65.7 - $83.98 $66,094 - $84,483	-1,006 Reduced 2.64%	37,095 $2.7 Million
Q1 2019 Apr 16, 2019	BUY	$77.14 - $90.79 $364,872 - $429,436	4,730 Added 14.17%	38,101 $3.07 Million
Q4 2018 Jan 17, 2019	SELL	$77.85 - $96.01 $13,623 - $16,801	-175 Reduced 0.52%	33,371 $3.08 Million
Q3 2018 Oct 22, 2018	BUY	$88.91 - $98.84 $8,446 - $9,389	95 Added 0.28%	33,546 $3.17 Million
Q2 2018 Jul 25, 2018	SELL	$89.78 - $106.23 $86,099 - $101,874	-959 Reduced 2.79%	33,451 $3.1 Million
Q1 2018 Apr 11, 2018	SELL	$92.01 - $123.21 $22,082 - $29,570	-240 Reduced 0.69%	34,410 $3.26 Million
Q4 2017 Jan 16, 2018	SELL	$89.56 - $98.21 $107,203 - $117,557	-1,197 Reduced 3.34%	34,650 $3.48 Million
Q3 2017 Oct 16, 2017	BUY	$69.85 - $89.22 $2.5 Million - $3.2 Million	35,847	35,847 $3.19 Million

Others Institutions Holding ABBV

# of Institutions

3,852

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Edmp, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Edmp, Inc. with notifications on news.

Account